Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what plans they have to ensure that people with multiple sclerosis currently accessing beta interferon and glatiramer acetate through the Risk Sharing Scheme continue to access these treatments after data collection for the Scheme ends in summer 2015.

The end of data collection for the Multiple Sclerosis Risk Sharing Scheme will not affect the availability of the beta interferons and glatiramer acetate through the Scheme. The NHS Commissioning Board and Clinical Commissioning Group (Responsibilities and Standing Rules) Regulations 2012 require commissioners to fund the provision of the Scheme drugs for those patients who meet the clinical guidelines.